Home Sitemap Contact us Accessibility Statement Top of the page
  • DuoResp® Spiromax®

    DuoResp® Spiromax®

    (budesonide/formoterol fumarate dihydrate)

Prescribing DuoResp Spiromax®

DuoResp Spiromax® (budesonide/formoterol fumarate dihydrate) a multi-dose dry-powder inhaler for the management of asthma and Chronic Obstructive Pulmonary Disease.

Available as:

  • DuoResp Spiromax® 160mcg/4.5mcg dry powder inhaler. 
    Each delivered dose (the dose that leaves the mouthpiece of the Spiromax®) contains 160mcg of budesonide and 4.5mcg of formoterol fumarate dihydrate. This is equivalent to a metered dose of 200mcg budesonide and 6mcg of formoterol fumarate dihydrate.
  • DuoResp Spiromax® 320mcg/9mcg dry powder inhaler.
    Each delivered dose (the dose that leaves the mouthpiece of the Spiromax®) contains 320mcg of budesonide and 9mcg of formoterol fumarate dihydrate. This is equivalent to a metered dose of 400mcg budesonide and 12mcg of formoterol fumarate dihydrate.1

The Spiromax® Device

Patients have been known to express a preference for a specific inhaler device. This can make it easier to teach inhaler technique as well as increasing the likelihood of correct use while decreasing the chance of non-compliance.2

Poor inhaler technique can lead to poor control of asthma and COPD. It may result in reduced lung deposition,3 increased symptoms and exacerbations,4,5 potentially leading to emergency hospital admissions.

DuoResp Spiromax® has an award-winning design6 with the effective combination of drugs you know.

DuoResp Spiromax® is ready in one flip of a cover with consistent dose delivery in real-word conditions7 and dose confirmation. It works across inspiratory flow rates (~30-90 L/min).7,8

In addition to the healthcare professional and patient benefits, DuoResp Spiromax® could potentially provide annual savings of £40.8 million to the NHS.9

About DuoResp Spiromax®

Therapeutic indications
DuoResp Spiromax® is indicated in adults 18 years of age and older only.1

Asthma

DuoResp Spiromax® is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:

  • in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.
    or,
  • in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.1

Chronic Obstructive Pulmonary Disease

Symptomatic treatment of patients with severe COPD (FEV1 < 70% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1

Marketing Authorisation

Teva Pharma B.V.
Swensweg 5,
2031GA Haarlem
The Netherlands

Marketing Authorisation number(s)

  • EU/1/14/920/001-006

Visit the DuoResp Spiromax® Website

Visit www.duoresp.co.uk for more information

Resources for DuoResp Spiromax®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect

Medicine supporting documentation for DuoResp Spiromax®
  • Summary of Product Characteristics - DuoResp Spiromax® 160 micrograms/4.5 micrograms inhalation powder
    View Document >
  • Summary of Product Characteristics - DuoResp Spiromax® 320 micrograms/9 micrograms inhalation powder
    View Document >
  • Patient Information Leaflet - DuoResp Spiromax® 160 micrograms/4.5 micrograms inhalation powder
    View Document >
  • Patient Information Leaflet - DuoResp Spiromax® 320 micrograms/9 micrograms inhalation powder
    View Document >

1. DuoResp Spiromax® 320 micrograms/9 micrograms and 160 micrograms/4.5 micrograms inhalation powder - Summary of Product Characteristics

2 Price D et al. Resp Med 2013; 107:37-46

3 Giraud V, Roche N. Eur Resp J 2002; 19:246-251

4 Melani AS et al. Resp Med 2011; 105:930-938

5 Kemp L et al. Clinicoecon Outcomes Res 2010; 2:75-85

6 http://www.devicelink.com/expo/awards/awards/index.php?catld=-1&year=2015&view=View Last accessed March 2016

7 Canonica G et al. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015; 28(5): 309-19.

8 Chrystyn H et al. Int J Pharm, 2015; 491: 268-76.

9 HSCIC England, Wales NHS, HSCNI Northern Ireland, September 2013 to August 2014. ISD Scotland, July 2013 to June 2014

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a